Hormonal
Tirzepatide treatment in adults with obesity but without pre-existing type 2 diabetes significantly reduces the incidence of new-onset type 2 diabetes compared to semaglutide.
If you have obesity and are at risk for type 2 diabetes, tirzepatide may be a more effective option than semaglutide for preventing the onset of the disease. This is based on real-world data showing a 27% lower risk of developing type 2 diabetes with tirzepatide compared to semaglutide over a one-year follow-up period. Consult your doctor to see if this treatment is appropriate for you.
Tirzepatide was associated with both lower risk for incident T2D (HR 0.73, 95% CI 0.58–0.92, p < 0.001)... compared to semaglutide
Why this rating
Large retrospective cohort study (n=13,846) with propensity score matching, but observational design limits causal inference compared to RCTs.
Source
Incidence of new onset type 2 diabetes in adults living with obesity treated with tirzepatide or semaglutide: real world evidence from an international retrospective cohort study
Matthew Anson et al. · EClinicalMedicine · 2024
DOI 10.1016/j.eclinm.2024.102777
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →